The View on GU | with Lalani and Wallis copertina

The View on GU | with Lalani and Wallis

The View on GU | with Lalani and Wallis

Di: Dr. Aly-Khan Lalani & Dr. Christopher Wallis
Ascolta gratuitamente

Offerte di stagione | 0,99 €/mese per i primi 3 mesi

A seguire 9,99 €/mese – si applicano condizioni. Puoi disdire mensilmente.
A proposito di questo titolo
There is currently a lack of organic multi-disciplinary discussion on what is truly impactful to the field of genitourinary (GU) cancers. The View on GU with Lalani and Wallis is a podcast that will integrate key clinical data from major conferences and high impact publications into meaningful take home messages for practicing clinicians. Importantly, Lalani and Wallis will also discuss the impact of governmental approvals and funding considerations on the GU oncology treatment landscape and provide practical considerations on the management of patients on new-to-market therapies.Dr. Aly-Khan Lalani & Dr. Christopher Wallis Disturbo fisico e malattia Igiene e vita sana
  • Episode 47: ESMO 2026 Commentary: Prostate Cancer
    Nov 5 2026

    Rounding out their three-part coverage from the ESMO 2026 Congress in Madrid, Dr. Aly-Khan Lalani and Dr. Christopher Wallis welcome special guest Dr. Sébastien Hotte to explore the latest developments in prostate cancer research and treatment.

    The conversation begins with findings from the DASL-HiCaP trial, examining the role of darolutamide alongside androgen deprivation therapy (ADT) and radiation therapy in very high-risk localized prostate cancer. The discussion also revisits the PROTEUS trial, highlighting new data from its surgical substudy, evolving approaches to treatment intensification, and the importance of multidisciplinary collaboration in optimizing patient care.

    Turning to emerging therapies, the panel explores promising early findings involving RIPTAC molecules and their novel mechanism of action. They also review updated evidence from PEACE-1 andquality-of-life findings from the PR.21 trial, considering how these advances may shape treatment decisions in metastatic prostate cancer.

    The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

    This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Ferring, Pfizer, Tolmar, AbbVie, Astellas, Ipsen, Merck, Bayer, TerSera.

    Mostra di più Mostra meno
    41 min
  • Episode 46: ESMO 2026 Commentary: Kidney Cancer
    Nov 5 2026

    Continuing their coverage from ESMO 2026 in Madrid, Dr. Aly-Khan Lalani and Dr. Christopher Wallis turn their attention to kidney cancer, highlighting the latest research and emerging approaches to the treatment of renal cell carcinoma (RCC).

    The discussion begins with long-term follow-up data from KEYNOTE-564, examining the sustained benefits of adjuvant pembrolizumab and the importance of balancing treatment outcomes with patient experience. They also explore findings from the PE-PE trial, considering the potential role of immunotherapy alongside metastasis-directed treatment in oligometastatic RCC.

    Turning to advanced disease, Dr. Lalani and Dr. Wallis review the LITESPARK-012 and LITESPARK-011 trials, discussing treatment combinations, progression-free and overall survival outcomes, and the challenges of balancing efficacy with toxicity. The conversation also highlights emerging research onbispecific T-cell engagers, including early findings from the XmAb819 trial, offering a glimpse into the future of kidney cancer treatment.

    The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

    This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Ferring, Pfizer, Tolmar, AbbVie, Astellas, Ipsen, Merck, Bayer, TerSera.

    Mostra di più Mostra meno
    30 min
  • Episode 45: ESMO 2026 Commentary: Bladder Cancer
    Nov 5 2026

    Recorded in Madrid at ESMO 2026, Dr. Aly-Khan Lalani and Dr. Christopher Wallis kick off a three-part series highlighting the latest advances in GU cancer care, beginning with bladder cancer.

    With perioperative treatment for muscle-invasive bladder cancer evolving rapidly, Dr. Lalani and Dr. Wallis revisit the NIAGARA trial alongside emerging findings from ENERGIZE and KEYNOTE-866, comparing key trial outcomes and exploring their potential implications for clinical practice.

    The conversation also explores emerging ctDNA biomarker data from KEYNOTE-B15/EV-304, new findings from KEYNOTE-905/EV-303, and the highly anticipated VOLGA trial. Dr. Lalani and Dr. Wallis examine the evolving roles of antibody-drug conjugates and immunotherapy, weighing treatment efficacy against potential toxicity, and highlighting the questions that remain around optimizing perioperative care.

    The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

    This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Ferring, Pfizer, Tolmar, AbbVie, Astellas, Ipsen, Merck, Bayer, TerSera.

    Mostra di più Mostra meno
    40 min
adbl_web_anon_alc_button_suppression_t1
Ancora nessuna recensione